Five-year study results indicate that BioPoly’s Knee Partial Resurfacing implant was safe, provided significant improvement starting at six months and continuing to five years, and provided greater improvement than microfracture for some outcome measures.
The BioPoly Knee System is indicated for partial resurfacing in the femoral condyle or trochlear facet and can be used with or without bone cement. This implant provides an early intervention option to address cartilage damage using bone-sparing and minimally invasive techniques. According to Sheila Schwartz, RPh, COO and Co-Founder of BioPoly, “Running this five-year UK study from the US has not been an easy task; however, it is so rewarding because patients are truly benefiting with real pain reduction and improved activity levels over a long period of time.”
Ryan Schlotterback, President & CEO of BioPoly, said, “We believe these results continue to demonstrate the value and clinical efficacy of our BioPoly technology in the exciting early intervention market. Given our recent Breakthrough Device designation by FDA in April and these recently published results, we continue to actively work to accelerate our BioPoly knee system into the US market. Our knee system will be available in the US via our approved clinical trial in the coming months.”
“We remain focused on the sales expansion of our FDA-cleared and commercially available extremity portfolio. We are excited about supporting our Knee Study here in the US and believe that the release of our BioPoly Knee System in the US market is a critical step in our overall strategy and commercial growth plan,” said Justin J. Kaler, Vice President of Sales and Marketing.
Five-year study results indicate that BioPoly’s Knee Partial Resurfacing implant was safe, provided significant improvement starting at six months and continuing to five years, and provided greater improvement than microfracture for some outcome measures.
The BioPoly Knee System is indicated for partial resurfacing in the femoral condyle...
Five-year study results indicate that BioPoly’s Knee Partial Resurfacing implant was safe, provided significant improvement starting at six months and continuing to five years, and provided greater improvement than microfracture for some outcome measures.
The BioPoly Knee System is indicated for partial resurfacing in the femoral condyle or trochlear facet and can be used with or without bone cement. This implant provides an early intervention option to address cartilage damage using bone-sparing and minimally invasive techniques. According to Sheila Schwartz, RPh, COO and Co-Founder of BioPoly, “Running this five-year UK study from the US has not been an easy task; however, it is so rewarding because patients are truly benefiting with real pain reduction and improved activity levels over a long period of time.”
Ryan Schlotterback, President & CEO of BioPoly, said, “We believe these results continue to demonstrate the value and clinical efficacy of our BioPoly technology in the exciting early intervention market. Given our recent Breakthrough Device designation by FDA in April and these recently published results, we continue to actively work to accelerate our BioPoly knee system into the US market. Our knee system will be available in the US via our approved clinical trial in the coming months.”
“We remain focused on the sales expansion of our FDA-cleared and commercially available extremity portfolio. We are excited about supporting our Knee Study here in the US and believe that the release of our BioPoly Knee System in the US market is a critical step in our overall strategy and commercial growth plan,” said Justin J. Kaler, Vice President of Sales and Marketing.
Copy to clipboard 
